ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

ClinicalTrials.gov ID: NCT07223021

Public ClinicalTrials.gov record NCT07223021. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Improving EveNt Free Survival by Optimizing FLUdarabine Exposure During LymphodepletioN for CAR T CEll Therapy: a Randomized, Multi-center Study of Children and Young Adults With B-cell Acute Lymphoblastic Leukemia (INFLUENCE)

Study identification

NCT ID
NCT07223021
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
130 participants

Conditions and interventions

Interventions

  • CAR-T Biological
  • Cyclophosphamide Drug
  • Fludarabine Drug

Biological · Drug

Eligibility (public fields only)

Age range
1 Year and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 19, 2025
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028
Last update posted
Mar 29, 2026

2025 – 2028

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
Cincinnati Children's Hospital Medical Center (Data Collection Only) Cincinnati Ohio 45229 Recruiting
Children's Hospital of Philadelphia (Data Collection Only) Philadelphia Pennsylvania 19104 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07223021, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07223021 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →